146 related articles for article (PubMed ID: 33099182)
1. Antibody drug conjugates of cleavable amino-benzoyl-maytansinoids.
Nittoli T; Delfino F; Kelly M; Carosso S; Markotan T; Kunz A; Chen Z; Mao S; Shan J; Navarro E; Zhao F; Makonnen S; Hickey C; Spink J; Olson W; Kirshner JR; Thurston G; Papadopoulos N
Bioorg Med Chem; 2020 Dec; 28(23):115785. PubMed ID: 33099182
[TBL] [Abstract][Full Text] [Related]
2. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
3. Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids.
Nittoli T; Kelly MP; Delfino F; Rudge J; Kunz A; Markotan T; Spink J; Chen Z; Shan J; Navarro E; Tait M; Provoncha K; Giurleo J; Zhao F; Jiang X; Hylton D; Makonnen S; Hickey C; Kirshner JR; Thurston G; Papadopoulos N
Bioorg Med Chem; 2018 May; 26(9):2271-2279. PubMed ID: 29605304
[TBL] [Abstract][Full Text] [Related]
4. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells.
Singh R; Setiady YY; Ponte J; Kovtun YV; Lai KC; Hong EE; Fishkin N; Dong L; Jones GE; Coccia JA; Lanieri L; Veale K; Costoplus JA; Skaletskaya A; Gabriel R; Salomon P; Wu R; Qiu Q; Erickson HK; Lambert JM; Chari RV; Widdison WC
Mol Cancer Ther; 2016 Jun; 15(6):1311-20. PubMed ID: 27197308
[TBL] [Abstract][Full Text] [Related]
5. Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells.
Salomon PL; Singh R
Mol Pharm; 2015 Jun; 12(6):1752-61. PubMed ID: 25738394
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of anti-CD38 antibody drug conjugate based on Daratumumab and maytansinoid.
Zhang X; Zhang C; Yang X; Hou X; Zhao W; Benson D; Yu J; Dong Y
Bioorg Med Chem; 2019 Feb; 27(3):479-482. PubMed ID: 30594452
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity with antibody maytansinoid conjugates: A review of preclinical and clinical findings.
Taplin S; Vashisht K; Walles M; Calise D; Kluwe W; Bouchard P; Johnson R
J Appl Toxicol; 2018 May; 38(5):600-615. PubMed ID: 29388692
[TBL] [Abstract][Full Text] [Related]
8. Maytansinoid-BODIPY Conjugates: Application to Microscale Determination of Drug Extinction Coefficients and for Quantification of Maytansinoid Analytes.
Fishkin N
Mol Pharm; 2015 Jun; 12(6):1745-51. PubMed ID: 25738231
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates.
Kolodych S; Michel C; Delacroix S; Koniev O; Ehkirch A; Eberova J; Cianférani S; Renoux B; Krezel W; Poinot P; Muller CD; Papot S; Wagner A
Eur J Med Chem; 2017 Dec; 142():376-382. PubMed ID: 28818506
[TBL] [Abstract][Full Text] [Related]
10. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.
Hamblett KJ; Le T; Rock BM; Rock DA; Siu S; Huard JN; Conner KP; Milburn RR; O'Neill JW; Tometsko ME; Fanslow WC
Mol Pharm; 2016 Jul; 13(7):2387-96. PubMed ID: 27248573
[TBL] [Abstract][Full Text] [Related]
11. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.
Whiteman KR; Johnson HA; Mayo MF; Audette CA; Carrigan CN; LaBelle A; Zukerberg L; Lambert JM; Lutz RJ
MAbs; 2014; 6(2):556-66. PubMed ID: 24492307
[TBL] [Abstract][Full Text] [Related]
12. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
[TBL] [Abstract][Full Text] [Related]
13. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.
Ponte JF; Sun X; Yoder NC; Fishkin N; Laleau R; Coccia J; Lanieri L; Bogalhas M; Wang L; Wilhelm S; Widdison W; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2016 Jul; 27(7):1588-98. PubMed ID: 27174129
[TBL] [Abstract][Full Text] [Related]
14. Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing.
Widdison WC; Ponte JF; Coccia JA; Lanieri L; Setiady Y; Dong L; Skaletskaya A; Hong EE; Wu R; Qiu Q; Singh R; Salomon P; Fishkin N; Harris L; Maloney EK; Kovtun Y; Veale K; Wilhelm SD; Audette CA; Costoplus JA; Chari RV
Bioconjug Chem; 2015 Nov; 26(11):2261-78. PubMed ID: 26355774
[TBL] [Abstract][Full Text] [Related]
15. Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs).
Hoffmann RM; Mele S; Cheung A; Larcombe-Young D; Bucaite G; Sachouli E; Zlatareva I; Morad HOJ; Marlow R; McDonnell JM; Figini M; Lacy KE; Tutt AJN; Spicer JF; Thurston DE; Karagiannis SN; Crescioli S
Sci Rep; 2020 Jun; 10(1):8869. PubMed ID: 32483228
[TBL] [Abstract][Full Text] [Related]
16. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
17. Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies.
Widdison W; Wilhelm S; Veale K; Costoplus J; Jones G; Audette C; Leece B; Bartle L; Kovtun Y; Chari R
Mol Pharm; 2015 Jun; 12(6):1762-73. PubMed ID: 25826705
[TBL] [Abstract][Full Text] [Related]
18. C3 ester side chain plays a pivotal role in the antitumor activity of Maytansinoids.
Li W; Huang M; Li Y; Xia A; Tan L; Zhang Z; Wang Y; Yang J
Biochem Biophys Res Commun; 2021 Aug; 566():197-203. PubMed ID: 34144258
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs).
Reid EE; Archer KE; Shizuka M; McShea MA; Maloney EK; Ab O; Lanieri L; Wilhelm A; Ponte JF; Yoder NC; Chari RVJ; Miller ML
Bioorg Med Chem Lett; 2019 Sep; 29(17):2455-2458. PubMed ID: 31350125
[TBL] [Abstract][Full Text] [Related]
20. Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates.
Goldmacher VS; Amphlett G; Wang L; Lazar AC
Mol Pharm; 2015 Jun; 12(6):1738-44. PubMed ID: 25635630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
